Show simple item record

dc.contributor.authorBhuiyan, Mejbah Uddin
dc.contributor.authorLuby, Stephen P.
dc.contributor.authorAlamgir, Nadia Ishrat
dc.contributor.authorHomaira, Nusrat
dc.contributor.authorSturm-Ramirez, Katharine M.
dc.contributor.authorGurley, Emily Suzane
dc.contributor.authorAbedin, Jaynal
dc.contributor.authorZaman, Rashid Uz
dc.contributor.authorAlamgir, Asm S.M.
dc.contributor.authorRahman, Mahmudur M.Atiqur
dc.contributor.authorOrtega-Sánchez, Ismael R.
dc.contributor.authorAzziz-Baumgartner, Eduardo
dc.identifier.citationBhuiyan, M. U., Luby, S. P., Alamgir, N. I., Homaira, N., Sturm-Ramirez, K., Gurley, E. S., . . . Azziz-Baumgartner, E. (2017). Costs of hospitalization with respiratory syncytial virus illness among children aged < 5 years and the financial impact on households in bangladesh, 2010. Journal of Global Health, 7(1)10.7189/jogh.07.010412en_US
dc.descriptionThis article was published in the Journal of Global Health [© 2017 University of Edinburgh] The Journal's website is at:
dc.description.abstractBackground Respiratory syncytial virus (RSV) is the leading cause of acute respiratory illness in young children and results in significant economic burden. There is no vaccine to prevent RSV illness but a number of vaccines are in development. We conducted this study to estimate the costs of severe RSV illness requiring hospitalization among children <5 years and associated financial impact on households in Bangladesh. Data of this study could be useful for RSV vaccine development and also the value of various preventive strategies, including use of an RSV vaccine in children if one becomes available. Methods From May through October 2010, children aged < 5 years with laboratory-confirmed RSV were identified from a sentinel influenza program database at four tertiary hospitals. Research assistants visited case-patients' homes after hospital discharge and administered a structured questionnaire to record direct medical costs (physician consultation fee, costs for hospital bed, medicines and diagnostic tests); non-medical costs (costs for food, lodging and transportation); indirect costs (caregivers' productivity loss), and coping strategies used by families to pay for treatment. We used WHO-Choice estimates for routine health care service costs. We added direct, indirect and health care service costs to calculate cost-per-episode of severe RSV illness. We used Monte Carlo simulation to estimate annual economic burden for severe RSV illness. Findings We interviewed caregivers of 39 persons hospitalized for RSV illness. The median direct cost for hospitalization was US$ 62 (interquartile range [IQR] = 43-101), indirect cost was US$ 19 (IQR = 11-29) and total cost was US$ 94 (IQR = 67-127). The median out-of-pocket cost was 24% of monthly household income of affected families (US$ 143), and > 50% families borrowed money to meet treatment cost. We estimated that the median direct cost of RSV-associated hospitalization in children aged < 5 years in Bangladesh was US$ 10 million (IQR: US$ 7-16 million), the median indirect cost was US$ 3.0 million (IQR: 2-5 million) in 2010. Conclusion: RSV-associated hospitalization among children aged < 5 years represents a substantial economic burden in Bangladesh. Affected families frequently incurred considerable out of pocket and indirect costs for treatment that resulted in financial hardship.en_US
dc.publisher© 2017 University of Edinburghen_US
dc.subjectChild healthen_US
dc.subjectHospital costen_US
dc.titleCosts of hospitalization with respiratory syncytial virus illness among children aged < 5 years and the financial impact on households in Bangladesh, 2010en_US
dc.contributor.departmentJames P Grant School of Public Health, BRAC University

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record